• Indian Indices
  • Global Indices
  • Commodities
  • Currency
Sensex
  • Sensex
  • Nifty
{{x.close_price| number:2}} {{x.netchg| number:2}} ({{x.perchg | number:2}}%)
Open - {{x.open | number:2}}
Prev Close - {{x.prevclose|number:2}}
Today's High - {{x.high|number:2}}
Today's Low - {{x.low|number:2}}
Advances/Declines (30 Companies)
  • 1D
  • 1W
  • 1M
  • 1Yr
  • 5Yr
{{x.upd_time}}
FTSE 100
  • FTSE 100
  • DJIA
  • NIKKEI 225
  • HANG SENG
{{x.Date}}
{{x.close| number:2}} {{x.Chg | number:2}} ({{x.PChg | number:2}}%)
Open - {{x.close | number:2}}
Prev Close - {{x.PrevClose|number:2}}
Gold
  • Gold
  • Silver
  • Crude Oil
  • Copper
{{x.Trd_Date}} ( {{x.Time}} )
{{x.ClosePrice| number:2}} {{x.change| number:2}} ({{x.perchange | number:2}}%)
Exchange - MCX
Open - {{x.Open|number:2}}
Exp Date - {{x.Exp_Date}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevClose|number:2}}
Today's Low - {{x.Low|number:2}}
USDINR
  • USDINR
  • GBPINR
  • EURINR
  • JPYINR
{{x.Lasttrdtime}} ( {{x.Time}} )
{{x.ltp| number:2}} {{x.PriceDiff| number:2}} ({{x.PerChange | number:2}}%)
Exchange - NSE
Open - {{x.Open|number:2}}
Exp Date - {{x.Expirydate}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevPrice|number:2}}
Today's Low - {{x.Low|number:2}}
As On 03-Feb-2023 EOD, Market Closed
SENSEX
60,841.88
909.64 (1.52%)
NIFTY
17,854.05
243.65 (1.38%)
    No Companies Visited

Back to news list
  • Dr. Reddy's Labs gains after Q2 PAT rises 12% YoY

    Dr. Reddy's Laboratories rose 1.99% to Rs 4549.80 after the drug maker reported 12% growth in consolidated net profit to Rs 11,128 crore in Q2 FY23 as compared with a PAT of Rs 9,920 crore recorded in the same period last year.

    Revenues improved by 9% YoY to Rs 63,057 crore in the second quarter. The company had posted a revenue of Rs 57,632 crore in the same period last year. On the segmental front, Global Generics business posted a revenue of Rs 55,946 crore (up 18% YoY) Pharmaceutical Services and Active Ingredients revenue was Rs 6,434 crore (down 23% YoY) and 'Others' revenue was Rs 677 crore (down 63% YoY) in the second quarter. In the Global Generics segment, North America recorded revenue growth of 48% YoY, followed by Europe (up 2% YoY) and India (up 1% YoY). Emerging Markets division, however, witnessed a contraction in revenue of 6% on YoY basis.

    Profit before tax in Q2 FY23 stood at Rs 16,111 crore, up by 27% from Rs 12,681 crore in Q2 FY22.

    Research and Development expenses rose by 9% YoY to Rs 4,869 crore in Q2 FY23.

    G V Prasad, co-chairman & MD, said: "We are pleased with the strong financial performance in the current quarter, driven by the launch of Lenalidomide capsules in the US market. Our focus is to build a robust pipeline with products that improve affordability and access to patients to progress well in our productivity, innovation and sustainability agenda.”

    Dr Reddy's Labs is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.



    Back to news list
Previous Stories :
More






Hot Pursuit News

Quick Links

Market Statistics

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Capital Market Publishers India Pvt. Ltd.

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071.
91-22-25229720
9769005430
Kindly note www.capitalmarket.com does not send any mobile SMS, whatsapp or twitter messages
giving any kind of stock recommendations.
For Capital Market Magazine queries mail to : subscription@capitalmarket.com
For Capital Market Online Products related queries mail to : financeshop@capitalmarket.com
For any other Capital Market Website related Queries mail to : info@capitalmarket.com
To advertise on Capital Market Websites & Capital Market Fortnightly magazine mail to : advt@capitalmarket.com
Flash News 04-Feb-2023
  •  ( 12:28) ITC Q3 PAT rises 21% YoY to Rs 5,031 cr; dividend at Rs 6/shr  
Show News
03 February 2023 00:00
2760.15
(2.01 %)
882.75
(1.65 %)
6010.75
(5.13 %)
1337.50
(5.15 %)
793.05
(2.00 %)
2695.00
(3.15 %)
1145.80
(-0.16 %)
1658.70
(3.46 %)
2645.90
(0.44 %)
863.75
(0.73 %)
1103.50
(2.61 %)
1599.15
(1.00 %)
380.50
(0.50 %)
1780.50
(1.03 %)
2166.80
(0.99 %)
1388.05
(2.61 %)
8943.10
(0.84 %)
19010.05
(0.27 %)
165.50
(-0.69 %)
214.85
(0.96 %)
2329.05
(0.10 %)
544.45
(3.12 %)
1027.65
(1.95 %)
445.45
(0.18 %)
120.10
(0.17 %)
3481.85
(0.57 %)
1012.05
(-0.41 %)
2463.20
(6.87 %)
7185.40
(0.19 %)
407.80
(-0.32 %)
Sensex 5min and Nifty 15min delayed as on .
Show Ticker
Rotate your device

Rotate your device

For the best experience please go back to portrait mode.